Pediatric HIV and Cancer Epidemiology
儿童艾滋病毒和癌症流行病学
基本信息
- 批准号:10223901
- 负责人:
- 金额:$ 17.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-25 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:14 year oldAIDS related cancerAIDS/HIV problemAcquired Immunodeficiency SyndromeAcuteAddressAdultAfricaAfrica South of the SaharaBiological MarkersBloodCancer BurdenCaringCellsChildChildhoodClinicClinicalClinical DataCollectionComputerized Medical RecordDataDiagnosisDiseaseEnvironmentEpidemiologyFutureGoalsHIVHIV InfectionsHuman Herpesvirus 4Human Herpesvirus 8ImmuneImmune systemIncidenceInfectionInternationalInvadedKaposi SarcomaLaboratoriesLifeLiteratureLymphomaMalignant Childhood NeoplasmMalignant NeoplasmsMalnutritionMedicinePediatric HospitalsPediatric epidemiologyPlasmaPopulationPrevalenceProtocols documentationRecording of previous eventsResearchResourcesRiskRisk FactorsScreening for cancerSeveritiesSiteSystemTexasTimeUpdateUrsidae FamilyViral Load resultViral MarkersVirusantiretroviral therapybasecancer biomarkerscancer diagnosiscancer epidemiologycancer riskchemokineclinical riskcohortcollegecomorbiditycytokineepidemiology studyexperiencehigh riskhigh risk populationinfection related cancernovelpediatric human immunodeficiency virusrisk prediction
项目摘要
Project 1: Epidemiology of and Risk Prediction for Childhood Cancers in the Context of HIV/AIDS in
Africa
Sub-Saharan Africa (SSA) disproportionately bears the burden of pediatric HIV/AIDS, having approximately
90% of the 1.7 million pediatric cases of HIV. While substantial progress has been made in recent years to
limit the number of new cases of HIV among children, there are still an estimated 1.6 million children living with
HIV in SSA. These HIV-infected children are at a higher risk for developing cancer as a result of their disease.
The epidemiology of HIV-related malignancies among adults has been fairly extensively studied; however, few
epidemiologic studies on cancer among children with HIV have been conducted. Our long-term goal is to
determine which HIV-infected children are at highest risk of developing a malignancy. To address these gaps
in the epidemiology of pediatric HIV-related malignancies in SSA, we propose the following aims:
1. Calculate the prevalence and incidence of cancers among HIV+ children by expanding and updating
a cohort of HIV+ children who are treated and followed at the BIPAI Centers of Excellence.
We will leverage both the high-quality electronic medical record system in the BIPAI CoE and affiliated clinic
network and the large population of HIV-infected children who have been treated at the CoEs since 2004 to
understand the distribution of cancers in this high-risk population. Hypotheses: 1) The incidence of certain
infection-related cancers will be higher among HIV-infected children age 14 years or younger, and 2) there will
be a lower incidence of HIV-associated cancers (e.g., KS) over the timeframe of this cohort compared to
historical data, while the incidence of other non-AIDS defining cancers will be higher.
2. Determine the impact of clinical risk factors on pediatric HIV-related malignancy risk in SSA.
We will assess the impact of risk factors such as timing of anti-retroviral treatment, HIV stage at cancer
diagnosis, severe acute malnutrition at cancer diagnosis, and geoclimatic differences on HIV-related
malignancy risk of children living in SSA. We will also assess whether risk of developing HIV-related
malignancies is influenced by history of infections and other co-morbidities. Hypothesis: Factors related to a
child's HIV infection severity and early life environment underlie risk of developing pediatric HIV-related
malignancies in SSA.
3. Identify plasma biomarkers that are more abundant among HIV+ children diagnosed with cancer.
Based on evidence from the literature and our own preliminary data, we will compare a standard set of
cytokines/chemokines, and markers of virus burden, in 4 groups of children: 1) HIV+/Cancer+, 2) HIV+/Cancer-,
3) HIV-/Cancer+, and 4) HIV-/Cancer-. The goal is to identify biomarkers of cancer risk in HIV+ children that
could be utilized with the clinical factors identified in Aim 2 to develop a novel paradigm for cancer screening in
this high-risk population. Hypothesis: There are both specific cancer- and HIV-related differences detectable
in the plasma of children who develop HIV-related malignancies compared to those who do not.
项目1:艾滋病毒/艾滋病背景下的儿童癌症流行病学和风险预测
非洲
撒哈拉以南非洲(SSA)承担着不成比例的儿科艾滋病毒/艾滋病负担,
170万儿童艾滋病病例中的90%。虽然近年来取得了重大进展,
尽管限制了儿童中艾滋病毒新病例的数量,但估计仍有160万儿童感染艾滋病毒,
艾滋病在SSA这些感染艾滋病毒的儿童由于其疾病而患癌症的风险更高。
成人中HIV相关恶性肿瘤的流行病学已得到相当广泛的研究;然而,
对感染艾滋病毒的儿童进行了癌症流行病学研究。我们的长期目标是
确定哪些感染艾滋病毒的儿童患恶性肿瘤的风险最高。弥补这些差距
在SSA儿童HIV相关恶性肿瘤的流行病学中,我们提出以下目标:
1.计算艾滋病毒阳性儿童中癌症的流行率和发病率,
一群在BIPAI卓越中心接受治疗和随访的艾滋病毒阳性儿童。
我们将利用BIPAI卓越中心和附属诊所的高质量电子病历系统
自2004年以来,有大量艾滋病毒感染儿童在欧洲委员会接受治疗,
了解癌症在这一高危人群中的分布情况。假设:1)某些疾病的发病率
感染相关癌症在14岁或14岁以下的艾滋病毒感染儿童中会更高,2)
艾滋病毒相关癌症的发病率较低(例如,KS)在该队列的时间范围内,
根据历史数据,而其他非艾滋病定义的癌症的发病率将更高。
2.确定临床危险因素对SSA儿童HIV相关恶性肿瘤风险的影响。
我们将评估风险因素的影响,如抗逆转录病毒治疗的时间,艾滋病毒在癌症阶段
诊断,癌症诊断时严重急性营养不良,以及艾滋病毒相关的地理气候差异
生活在SSA的儿童的恶性肿瘤风险。我们还将评估是否有风险发展艾滋病毒相关的
恶性肿瘤受感染史和其他合并症的影响。假设:与a相关的因素
儿童的艾滋病毒感染严重程度和早期生活环境是儿童艾滋病毒相关疾病风险的基础。
SSA中的恶性肿瘤。
3.确定在被诊断患有癌症的HIV+儿童中更丰富的血浆生物标志物。
根据文献中的证据和我们自己的初步数据,我们将比较一组标准的
细胞因子/趋化因子和病毒负荷标志物,在4组儿童中:1)HIV+/癌症+,2)HIV+/癌症-,
3)HIV-/癌症+,和4)HIV-/癌症-。目标是确定HIV阳性儿童癌症风险的生物标志物,
可以与目标2中确定的临床因素一起使用,以开发一种新的癌症筛查模式,
这个高危人群。假设:可以检测到与癌症和艾滋病毒相关的特定差异
与未患艾滋病相关恶性肿瘤的儿童相比,
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael E Scheurer其他文献
Germline Genetic Testing and Survival Outcomes Among Children With Rhabdomyosarcoma
横纹肌肉瘤儿童的种系基因检测和生存结果
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:13.8
- 作者:
Bailey A Martin;He Li;Michael E Scheurer;Dana L Casey;Shannon Dugan;Deborah A Marquez;D. Muzny;Richard A. Gibbs;D. Barkauskas;David Hall;Douglas R Stewart;J. Schiffman;Matthew T McEvoy;Javed Khan;D. Malkin;C. Linardic;B. Crompton;J. Shern;S. Skapek;R. Venkatramani;Douglas S. Hawkins;A. Sabo;Sharon E. Plon;Philip J. Lupo - 通讯作者:
Philip J. Lupo
Michael E Scheurer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael E Scheurer', 18)}}的其他基金
Sex and racial/ethnic differences in B-ALL genomics
B-ALL 基因组学中的性别和种族/民族差异
- 批准号:
10555358 - 财政年份:2022
- 资助金额:
$ 17.22万 - 项目类别:
Ethnic disparities in methotrexate neurotoxicity among children and adolescents with ALL
患有 ALL 的儿童和青少年中甲氨蝶呤神经毒性的种族差异
- 批准号:
10289496 - 财政年份:2021
- 资助金额:
$ 17.22万 - 项目类别:
Admixture analysis of acute lymphoblastic leukemia in African American children: the ADMIRAL Study
非裔美国儿童急性淋巴细胞白血病的混合分析:ADMIRAL 研究
- 批准号:
10307680 - 财政年份:2021
- 资助金额:
$ 17.22万 - 项目类别:
Ethnic disparities in methotrexate neurotoxicity among children and adolescents with ALL
患有 ALL 的儿童和青少年中甲氨蝶呤神经毒性的种族差异
- 批准号:
10683990 - 财政年份:2021
- 资助金额:
$ 17.22万 - 项目类别:
Ethnic disparities in methotrexate neurotoxicity among children and adolescents with ALL
患有 ALL 的儿童和青少年中甲氨蝶呤神经毒性的种族差异
- 批准号:
10472703 - 财政年份:2021
- 资助金额:
$ 17.22万 - 项目类别:
相似海外基金
NCI AIDS RELATED CANCER COHORT STUDY (ACCS)
NCI 艾滋病相关癌症队列研究 (ACCS)
- 批准号:
6566071 - 财政年份:2001
- 资助金额:
$ 17.22万 - 项目类别:
NCI AIDS RELATED CANCER COHORT STUDY (ACCS)
NCI 艾滋病相关癌症队列研究 (ACCS)
- 批准号:
6423242 - 财政年份:2000
- 资助金额:
$ 17.22万 - 项目类别:
NCI AIDS RELATED CANCER COHORT STUDY (ACCS)
NCI 艾滋病相关癌症队列研究 (ACCS)
- 批准号:
6504219 - 财政年份:2000
- 资助金额:
$ 17.22万 - 项目类别:
NCI AIDS RELATED CANCER COHORT STUDY (ACCS)
NCI 艾滋病相关癌症队列研究 (ACCS)
- 批准号:
6303902 - 财政年份:1999
- 资助金额:
$ 17.22万 - 项目类别:
NCI AIDS RELATED CANCER COHORT STUDY (ACCS)
NCI 艾滋病相关癌症队列研究 (ACCS)
- 批准号:
6297230 - 财政年份:1998
- 资助金额:
$ 17.22万 - 项目类别:
NCI AIDS RELATED CANCER COHORT STUDY (ACCS)
NCI 艾滋病相关癌症队列研究 (ACCS)
- 批准号:
6263862 - 财政年份:1998
- 资助金额:
$ 17.22万 - 项目类别:
Search for specific modulators of the inflammatory resp onse in AIDS related cancer
寻找艾滋病相关癌症中炎症反应的特异性调节剂
- 批准号:
nhmrc : 960853 - 财政年份:1996
- 资助金额:
$ 17.22万 - 项目类别:
CARG - Research